A prominent transplant surgeon has stated that pig organs may eventually surpass human donor organs in quality for transplantation purposes. Dr. Robert Montgomery, who leads NYU Langone’s Transplant Institute, oversees a clinical trial involving genetically modified pig kidneys transplanted into living patients. The organs have undergone ten genetic modifications to minimize rejection responses in human recipients.
The trial has already completed its first transplant procedure, with another planned for January. Initial expectations include six patients receiving these engineered organs. If the FDA approves expansion, the program could accommodate an additional 44 transplants. This xenotransplantation approach addresses a critical shortage of available human organs for people in need.
The organ shortage represents a severe global health challenge. In the United Kingdom, data shows that more than 12,000 individuals died or were removed from transplant waiting lists over a decade without receiving organs. Trial participants include those deemed ineligible for conventional human kidney transplants or those unlikely to receive organs within five years of waiting.
Montgomery brings personal perspective to this work. He experienced multiple cardiac arrests and received a heart transplant in 2018. He has also pioneered other methods to expand organ availability, including domino-paired kidney exchanges where incompatible living donors are matched through chains of recipients. He has additionally advanced use of organs from donors with hepatitis C.
Montgomery explained that incremental improvements to human organ supply proved insufficient against growing demand. While xenotransplantation concepts existed for decades, recent genetic engineering breakthroughs made implementation feasible. He conducted the first gene-edited pig kidney transplant in 2021, providing crucial safety data.
Genetically modified pig organs offer distinct advantages because continuous genetic modifications can enhance performance over time, unlike fixed human organs. Research indicates that transplanting the pig’s thymus alongside the kidney can improve immune tolerance, potentially reducing or eliminating lifelong anti-rejection medications.
Previous pig organ transplants in humans produced mixed outcomes, though some living recipients retain functioning pig kidneys. Montgomery noted that kidneys and hearts show promise for xenotransplantation, while lungs present greater complexity. He expressed openness to receiving a pig heart himself in future scenarios.
